Merck's Keytruda shows overall survival benefit in ovarian cancer
Source: SeekingAlpha
2026-02-27 11:38:24 ET
More on Merck
- Health Care Q4 Dividend Roundup: Merck Offers Thicker Dividend Cushion Than AbbVie
- Merck: Why Investors Should Remain Bullish Despite Patent Risks
- Merck: Keytruda Remains Resilient Despite LOE Risks - Buy Upon Correction
- FDA reportedly eyeing staff bonuses to accelerate drug reviews
- 15 states sue Trump administration over changes to U.S. vaccine schedule
Read the full article on Seeking Alpha
For further details see:
Merck's Keytruda shows overall survival benefit in ovarian cancer
Astellas Pharma Inc
NASDAQ: ALPMF
ALPMF Trading
14.55% G/L:
$16.38 Last:
323 Volume:
$16.38 Open:
ALPMF Latest News
ALPMF Stock Data
$28,999,226,915
1,808,873,137
N/A
N/A
Pharmaceuticals
Healthcare
JP
Chuo-Ku
